[go: up one dir, main page]

MX2024005157A - 2-(aril-2-il)morfolina y derivado deuterado de esta, metodo de preparacion de estos y aplicacion de estos. - Google Patents

2-(aril-2-il)morfolina y derivado deuterado de esta, metodo de preparacion de estos y aplicacion de estos.

Info

Publication number
MX2024005157A
MX2024005157A MX2024005157A MX2024005157A MX2024005157A MX 2024005157 A MX2024005157 A MX 2024005157A MX 2024005157 A MX2024005157 A MX 2024005157A MX 2024005157 A MX2024005157 A MX 2024005157A MX 2024005157 A MX2024005157 A MX 2024005157A
Authority
MX
Mexico
Prior art keywords
preparation
morpholine
aryl
application
deuterated
Prior art date
Application number
MX2024005157A
Other languages
English (en)
Inventor
Yidong Su
Haining Deng
Kailong Li
Zhiqiang Huang
Wensheng Yu
Xiaohan Zhou
Original Assignee
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hansoh Biomedical Co Ltd filed Critical Shanghai Hansoh Biomedical Co Ltd
Publication of MX2024005157A publication Critical patent/MX2024005157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan una 2-(aril-2-il) morfolina y un derivado deuterado de esta, un método de preparación de estos y una aplicación de estos. En particular, están involucrados el uso de un compuesto mostrado por la fórmula general (V) en el tratamiento de enfermedades del sistema nervioso central, un compuesto deuterado de este, un método de preparación del compuesto deuterado, una composición farmacéutica que contiene el compuesto deuterado y el uso de este como agonista de TAAR1 en el tratamiento de enfermedades del sistema nervioso central. (ver Fórmula).
MX2024005157A 2021-11-04 2022-11-04 2-(aril-2-il)morfolina y derivado deuterado de esta, metodo de preparacion de estos y aplicacion de estos. MX2024005157A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202111301874 2021-11-04
CN202210066119 2022-01-20
CN202210065986 2022-01-20
CN202210398665 2022-04-15
CN202211105290 2022-09-09
CN202211104724 2022-09-09
PCT/CN2022/129881 WO2023078392A1 (zh) 2021-11-04 2022-11-04 2-(芳基-2-基)吗啉及其氘代衍生物、制备方法和应用

Publications (1)

Publication Number Publication Date
MX2024005157A true MX2024005157A (es) 2024-05-29

Family

ID=86240672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005157A MX2024005157A (es) 2021-11-04 2022-11-04 2-(aril-2-il)morfolina y derivado deuterado de esta, metodo de preparacion de estos y aplicacion de estos.

Country Status (10)

Country Link
US (1) US20250051316A1 (es)
EP (1) EP4428128A1 (es)
JP (1) JP2024542057A (es)
KR (1) KR20240096681A (es)
CN (1) CN118176185A (es)
AU (1) AU2022381097A1 (es)
CA (1) CA3236619A1 (es)
MX (1) MX2024005157A (es)
TW (1) TW202325305A (es)
WO (1) WO2023078392A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222860A1 (zh) * 2023-04-28 2024-10-31 江苏豪森药业集团有限公司 一种吗啉杂环类化合物的盐及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2641648C1 (ru) 2009-12-04 2018-01-19 Суновион Фармасьютикалз, Инк. Полициклические соединения и способы их применения
ES2605632T3 (es) * 2012-09-17 2017-03-15 F. Hoffmann-La Roche Ag Derivados triazol carboxamida
WO2014072257A1 (en) * 2012-11-07 2014-05-15 F. Hoffmann-La Roche Ag Pyrazine derivatives
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives

Also Published As

Publication number Publication date
JP2024542057A (ja) 2024-11-13
CA3236619A1 (en) 2023-05-11
KR20240096681A (ko) 2024-06-26
WO2023078392A1 (zh) 2023-05-11
TW202325305A (zh) 2023-07-01
EP4428128A1 (en) 2024-09-11
US20250051316A1 (en) 2025-02-13
AU2022381097A1 (en) 2024-05-16
CN118176185A (zh) 2024-06-11

Similar Documents

Publication Publication Date Title
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CL2020002696A1 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
ECSP109934A (es) Compuesto - 946
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
MX2020003993A (es) Derivados de bencimidazol y sus usos.
CO2022008313A2 (es) Compuestos químicos
DOP2022000035A (es) Composiciones que comprenden tigolaner para el control de parásitos
CR20190379A (es) Moduladores del receptor de estrógeno
UY37445A (es) Derivados novedosos de napitridinona y su uso en el tratamiento de la arritmia
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
MX2024005157A (es) 2-(aril-2-il)morfolina y derivado deuterado de esta, metodo de preparacion de estos y aplicacion de estos.
CO2022014886A2 (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
UY39793A (es) Derivados heterocíclicos condensados
CL2021002430A1 (es) Formulación de tableta vaginal
UY39550A (es) Derivados heterocíclicos condensados
CU24543B1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
BR112019006371A2 (pt) compostos, composições farmacêuticas, uso de um composto ou composição e kits
DOP2024000096A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
MX2022004473A (es) Modificador de un derivado de anillo de cuatro miembros, metodo de preparacion y aplicacion del mismo.